Low Serum 25-hydroxyvitamin D (Vitamin D) Level Is Associated With Susceptibility to COVID-19, Severity, and Mortality: A Systematic Review and Meta-Analysis

Background: This systematic review and meta-analysis aimed to assess whether low serum 25-hydroxyvitamin D (25-OHD) level is associated with susceptibility to COVID-19, severity, and mortality related to COVID-19.Methods: Systematic literature searches of PubMed, Scopus, and Embase database up until 9 December 2020. We include published observational prospective and retrospective studies with information on 25-OHD that reported main/secondary outcome. Low serum 25-OHD refers to participants with serum 25-OHD level below a cut-off point ranging from 20 to 30 ng/mL. Other cut-off values were excluded to reduce heterogeneity. The main outcome was mortality defined as non-survivor/death. The secondary outcome was susceptibility and severe COVID-19.Results: There were 14 studies comprising of 999,179 participants. Low serum 25-OHD was associated with higher rate of COVID-19 infection compared to the control group (OR = 2.71 [1.72, 4.29], p < 0.001; I2: 92.6%). Higher rate of severe COVID-19 was observed in patients with low serum 25-OHD (OR = 1.90 [1.24, 2.93], p = 0.003; I2: 55.3%), with a sensitivity of 83%, specificity of 39%, PLR of 1.4, NLR of 0.43, and DOR of 3. Low serum 25-OHD was associated with higher mortality (OR = 3.08 [1.35, 7.00], p = 0.011; I2: 80.3%), with a sensitivity of 85%, specificity of 35%, PLR of 1.3, NLR of 0.44, and DOR of 3. Meta-regression analysis showed that the association between low serum 25-OHD and mortality was affected by male gender (OR = 1.22 [1.08, 1.39], p = 0.002), diabetes (OR = 0.88 [0.79, 0.98], p = 0.019).Conclusion: Low serum 25-OHD level was associated with COVID-19 infection, severe presentation, and mortality.

Download Full-text

Serum 25-Hydroxyvitamin D Levels and Prognosis in Hematological Malignancies: A Systematic Review and Meta-Analysis

Cellular Physiology and Biochemistry ◽

10.1159/000374007 ◽

2015 ◽

Vol 35 (5) ◽

pp. 1999-2005 ◽

Cited By ~ 22

Author(s):

Wei Wang ◽

Guangyun Li ◽

Xiaoyan He ◽

Jian Gao ◽

Robin Wang ◽

...

Keyword(s):

Systematic Review ◽

Hematological Malignancies ◽

Meta Analysis ◽

Normal Serum ◽

Hematological Cancer ◽

Free Survival ◽

Hydroxyvitamin D ◽

Hazard Ratios ◽

25 Hydroxyvitamin D ◽

Low Serum

Background/Aims: Serum 25-hydroxyvitamin D [25(OH)D] levels proved to be associated with prognosis of patients with colorectal cancer or breast cancer, but its prognostic role in hematological malignancies was still unclear. A systematic review and meta-analysis was performed to comprehensively evaluate the association between serum 25(OH)D levels and prognosis of patients with hematological malignancies. Methods: We searched Pubmed, Embase, Web of Science, and Google Scholar for studies evaluating the association between serum 25(OH)D levels and prognosis of patients with hematological malignancies. The hazard ratios (HR) with 95% confidence intervals (95%CI) for overall survival (OS) or relapse-free survival (RFS) were pooled using meta-analysis. Results: Seven studies with a total of 2,643 patients with hematological cancer were finally included into the meta-analysis. Overall, compared with normal serum 25(OH)D levels, low serum 25(OH)D levels were significantly associated with both poorer OS (HR = 1.85, 95% CI 1.54-2.23, P <0.001) and poorer RFS (HR = 1.45, 95% CI 1.25 to 1.70, P <0.001) in hematological malignancies. Subgroup analysis further showed that low serum 25(OH)D levels were significantly associated with poorer OS and RFS in both lymphoma and leukemia. Conclusion: Low serum 25(OH)D levels are significantly associated with poorer prognosis in patients with hematological malignancies including lymphoma and leukemia.

Download Full-text

Corrigendum: Low Serum 25-hydroxyvitamin D (Vitamin D) Level Is Associated With Susceptibility to COVID-19, Severity, and Mortality: A Systematic Review and Meta-Analysis

Frontiers in Nutrition ◽

10.3389/fnut.2021.754539 ◽

2021 ◽

Vol 8 ◽

Author(s):

Mohammad Rizki Akbar ◽

Arief Wibowo ◽

Raymond Pranata ◽

Budi Setiabudiawan

Keyword(s):

Systematic Review ◽

Vitamin D ◽

Meta Analysis ◽

Hydroxyvitamin D ◽

25 Hydroxyvitamin D ◽

Low Serum

Download Full-text

Circulating 25-hydroxyvitamin D level and prognosis of lung cancer patients: A systematic review and meta-analysis

Bulletin du Cancer ◽

10.1016/j.bulcan.2017.05.001 ◽

2017 ◽

Vol 104 (7-8) ◽

pp. 675-682 ◽

Cited By ~ 2

Author(s):

Jian-Da Huang ◽

Chao-Hui Dong ◽

Sheng-Wen Shao ◽

Tong-Jie Gu ◽

Zhi-Lin Hu ◽

...

Keyword(s):

Lung Cancer ◽

Systematic Review ◽

Cancer Patients ◽

Meta Analysis ◽

Lung Cancer Patients ◽

Hydroxyvitamin D ◽

25 Hydroxyvitamin D

Download Full-text

Vitamin D and Type 1 Diabetes Risk: A Systematic Review and Meta-Analysis of Genetic Evidence

Nutrients ◽

10.3390/nu13124260 ◽

2021 ◽

Vol 13 (12) ◽

pp. 4260

Author(s):

Liana Najjar ◽

Joshua Sutherland ◽

Ang Zhou ◽

Elina Hyppönen

Keyword(s):

Systematic Review ◽

Vitamin D ◽

Type 1 Diabetes ◽

Meta Analysis ◽

Low Frequency ◽

Nucleotide Polymorphisms ◽

Hydroxyvitamin D ◽

Quantitative Synthesis ◽

25 Hydroxyvitamin D

Several observational studies have examined vitamin D pathway polymorphisms and their association with type 1 diabetes (T1D) susceptibility, with inconclusive results. We aimed to perform a systematic review and meta-analysis assessing associations between selected variants affecting 25-hydroxyvitamin D [25(OH)D] and T1D risk. We conducted a systematic search of Medline, Embase, Web of Science and OpenGWAS updated in April 2021. The following keywords “vitamin D” and/or “single nucleotide polymorphisms (SNPs)” and “T1D” were selected to identify relevant articles. Seven SNPs (or their proxies) in six genes were analysed: CYP2R1 rs10741657, CYP2R1 (low frequency) rs117913124, DHCR7/NADSYN1 rs12785878, GC rs3755967, CYP24A1 rs17216707, AMDHD1 rs10745742 and SEC23A rs8018720. Seven case-control and three cohort studies were eligible for quantitative synthesis (n = 10). Meta-analysis results suggested no association with T1D (range of pooled ORs for all SNPs: 0.97–1.02; p > 0.01). Heterogeneity was found in DHCR7/NADSYN1 rs12785878 (I2: 64.8%, p = 0.02). Sensitivity analysis showed exclusion of any single study did not alter the overall pooled effect. No association with T1D was observed among a Caucasian subgroup. In conclusion, the evidence from the meta-analysis indicates a null association between selected variants affecting serum 25(OH)D concentrations and T1D.

Download Full-text

Low serum 25-hydroxyvitamin D is associated with increased bladder cancer risk: A systematic review and evidence of a potential mechanism

The Journal of Steroid Biochemistry and Molecular Biology ◽

10.1016/j.jsbmb.2019.01.002 ◽

2019 ◽

Vol 188 ◽

pp. 134-140 ◽

Cited By ~ 3

Author(s):

Janet A. Dunn ◽

Kieran Jefferson ◽

Donald MacDonald ◽

Gulnaz Iqbal ◽

Rosemary Bland

Keyword(s):

Systematic Review ◽

Bladder Cancer ◽

Cancer Risk ◽

Potential Mechanism ◽

Bladder Cancer Risk ◽

Hydroxyvitamin D ◽

25 Hydroxyvitamin D ◽

Low Serum

Download Full-text

Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis

International Journal of Rheumatology ◽

10.1155/2019/1076189 ◽

2019 ◽

Vol 2019 ◽

pp. 1-10 ◽

Cited By ~ 11

Author(s):

John A. Cuenca ◽

Javier Balda ◽

Ana Palacio ◽

Larry Young ◽

Michael H. Pillinger ◽

...

Keyword(s):

Systematic Review ◽

Cardiovascular Disease ◽

Cardiovascular Events ◽

Randomized Clinical Trials ◽

Meta Analysis ◽

The United States ◽

Major Adverse Cardiovascular Events ◽

Control Group ◽

Embase Database ◽

Cvd Mortality

Background. Febuxostat is approved in the United States for the management of hyperuricemia in patients with gout. In November 2017 the FDA released a warning alert on a possible link between febuxostat and cardiovascular disease (CVD) reported in a single clinical trial. Objective. To conduct a systematic review and meta-analysis and assess the risk of major adverse cardiovascular events (MACE) in patients receiving febuxostat compared to a control group. Methods. We searched the MEDLINE and EMBASE database for studies published up until March 2018. We included randomized clinical trials (RCTs) that compared febuxostat to control groups including placebo and allopurinol. We calculated the pooled relative risk (RR) of MACE and cardiovascular disease (CVD) mortality with the corresponding 95% confidence intervals (CI). Results. Our search yielded 374 potentially relevant studies. Among the 25 RCTs included in the systematic review, 10 qualified for the meta-analysis. Among the 14,402 subjects included, the median age was 54 years (IQR 52-67) and 90% were male (IQR 82-96); 8602 received febuxostat, 5118 allopurinol, and 643 placebo. The pooled RR of MACE for febuxostat was 0.9; 95% CI 0.6-1.5 (p= 0.96) compared to the control. The RR of CV-related death for febuxostat was 1.29; 95% CI 1.01-1.66 (p=0.03). Conclusions. Compared with other SU-lowering treatments, febuxostat does not increase or decrease the risk of cardiovascular disease but may increase the risk of CVD death. More RCTs measuring cardiovascular safety as a primary outcome are needed to adequately evaluate the risk of CVD with febuxostat.

Download Full-text

Serum concentration of 25-hydroxyvitamin D in autism spectrum disorder: a systematic review and meta-analysis

European Child & Adolescent Psychiatry ◽

10.1007/s00787-015-0786-1 ◽

2015 ◽

Vol 25 (4) ◽

pp. 341-350 ◽

Cited By ~ 68

Author(s):

Tiantian Wang ◽

Ling Shan ◽

Lin Du ◽

Junyan Feng ◽

Zhida Xu ◽

...

Keyword(s):

Systematic Review ◽

Autism Spectrum Disorder ◽

Serum Concentration ◽

Meta Analysis ◽

Autism Spectrum ◽

Spectrum Disorder ◽

Hydroxyvitamin D ◽

25 Hydroxyvitamin D

Download Full-text

Hyaluronic acid for post sinus surgery care: systematic review and meta-analysis

The Journal of Laryngology & Otology ◽

10.1017/s0022215116009269 ◽

2017 ◽

Vol 131 (S1) ◽

pp. S2-S11 ◽

Cited By ~ 8

Author(s):

E Fong ◽

M Garcia ◽

C M Woods ◽

E Ooi

Keyword(s):

Systematic Review ◽

Hyaluronic Acid ◽

Endoscopic Sinus Surgery ◽

Meta Analysis ◽

Adhesion Formation ◽

Sinus Surgery ◽

Current Evidence ◽

Secondary Outcome ◽

Control Group ◽

Patient Reported

AbstractBackground:Wound healing after endoscopic sinus surgery may result in adhesion formation. Hyaluronic acid may prevent synechiae development. A systematic review was performed to evaluate the current evidence on the clinical efficacy of hyaluronic acid applied to the nasal cavity after sinus surgery.Methods:Studies using hyaluronic acid as an adjunct treatment following endoscopic sinus surgery for chronic rhinosinusitis were identified. The primary outcome was adhesion formation rates. A meta-analysis was performed on adhesion event frequency. Secondary outcome measures included other endoscopic findings and patient-reported outcomes.Results:Thirteen studies (501 patients) met the selection criteria. A meta-analysis of adhesion formation frequency on endoscopy demonstrated a lower risk ratio in the hyaluronic acid intervention group (42 out of 283 cases) compared to the control group (81 out of 282) of 0.52 (95 per cent confidence interval = 0.37–0.72). Hyaluronic acid use was not associated with any significant adverse events.Conclusion:Hyaluronic acid appears to be clinically safe and well tolerated, and may be useful in the early stages after sinus surgery to limit adhesion rate. Further research, including larger randomised controlled trials, is required to evaluate patient- and clinician-reported outcomes of hyaluronic acid post sinus surgery.

Download Full-text